Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo)
| العنوان: | Monitoring of peripheral lymphocyte and neutrophil counts to predict efficacy of nivolumab (nivo) |
|---|---|
| المؤلفون: | Junji Koyama, Noriko Yanagitani, Fumiyoshi Ohyanagi, Makoto Nishio, Shingo Nishikawa, Takeshi Horai, Yuichi Tambo, Tomoyo Oguri, Tomoaki Sonoda, Satoru Kitazono, Atsushi Horiike, Ryo Ariyasu, Natsuki Takano, Yosuke Kawashima, Masafumi Saiki |
| المصدر: | Journal of Clinical Oncology. 35:e20583-e20583 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Response rate (survey), Drug, Cancer Research, biology, business.industry, media_common.quotation_subject, Lymphocyte, Peripheral, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Immunology, biology.protein, Medicine, Non small cell, Nivolumab, Antibody, business, 030215 immunology, media_common |
| الوصف: | e20583 Background: Programmed death-1 (PD-1) antibody is a key drug for treating non-small cell lung cancer (NSCLC), but the response rate is about 20% in non-selected populations and efficacy is difficult to predict. We examined correlations between peripheral blood tests, including counts of lymphocytes (Lym), neutrophils (Neu), and C-reactive protein (CRP), and the efficacy of nivolumab (nivo) monotherapy. Methods: Eighty NSCLC patients treated with nivo (3mg/kg every 2 weeks) in our hospital between December 2015 and September 2016 were evaluated. Peripheral blood tests on day (d) 0 (the day before 1st nivo), d15 (the day of 2nd nivo), d29 (the day of 3rdnivo) were evaluated. Absolute counts and the change ratio (%) of Lym, Neu and CRP from baseline (d0) were calculated. Response to nivo was evaluated according to RECIST v1.1. Results: Response to nivo was partial response in 23 cases, stable disease in 13 and progressive disease (PD) in 44 patients (overall response rate, 28%; disease control rate, 45%). Absolute counts of Lym, Neu and CRP at baseline did not differ significantly between non-PD and PD (Lym, 1323/µl vs. 1376/µl; Neu, 4830/µl vs. 5189/µl; CRP, 3.48 mg/dl vs. 3.38 mg/dl). Neu was significantly increased from baseline to d15 and d29 in the PD population compared with the non-PD population (δNeu (d15): 25.2% vs. -6.3%, P= 0.008; δNeu (d29): 16.7% vs. -8.6%, P= 0.006). CRP was also significantly increased from baseline to d29 in the PD population compared with the non-PD population (δCRP: 60.1% vs. -21.2%, P= 0.010). In contrast, Lym was significantly increased from baseline to d29 in the non-PD population compared with the PD population (δLym: 9.6% vs. –6.7%, P= 0.010). Conclusions: Changes in peripheral blood test results after nivo differed between non-PD and PD populations. Monitoring of Neu and Lym and CRP may allow prediction of the efficacy of nivo. |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::ca3136051452ebe4ed3f2e054763b010Test https://doi.org/10.1200/jco.2017.35.15_suppl.e20583Test |
| رقم الانضمام: | edsair.doi...........ca3136051452ebe4ed3f2e054763b010 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|